Malaria prevention in the expatriate and long-term traveller
- Daniel O'Brien and Beverly Biggs
- Aust Prescr 2002;25:66-9
- 1 May 2002
- DOI: 10.18773/austprescr.2002.060
The prevention of malaria in expatriates and long-term travellers is complex. The traveller's doctor needs to consider the destination, the nature of the travel, the effectiveness and potential adverse effects of antimalarial medication, and the general health of the traveller. A preventative regimen can be devised combining several strategies including mosquito avoidance measures, chemoprophylaxis, emergency standby treatment and rapid self-diagnosis of malaria.
In 1999, 3.2 million Australians travelled abroad, and travel to countries where malaria is endemic is becoming increasingly common. Each year an estimated 30 000 cases of malaria occur in non-immune travellers worldwide.1 Many people, including aid workers, missionaries, students and healthcare workers, are travelling to work and live in rural and remote malarial regions. The estimated mortality rate for falciparum malaria in non-immune adults is up to 5%, so the medical practitioner entrusted with providing safe and suitable travel health advice will need to carefully consider the need for antimalarial prophylaxis. When the traveller's stay in an endemic area exceeds six months the issues can become quite complex.
There is no perfect choice of antimalarial regimen for long-term travellers and expatriates. Prevention involves careful consideration of a number of factors, which include:
These issues need to be discussed openly with the traveller. A mutually acceptable plan for malaria prevention can then be developed.
Protection against malaria in the long-term traveller can include some or all of the following:
These measures are the mainstay of any long-term antimalarial prophylaxis regimen. They are important in reducing the risk of contracting malaria in any traveller, but because of the many difficulties and limitations of chemoprophylaxis they are vital in long-term travellers. Adequate time must be spent with the patient to educate them about measures to reduce:
The currently available medications we feel should be considered are summarised in Table 1.
|Medication||Resistance*||Dose||Frequency||Pregnancy||Children||Time prior to entering a malarial endemic area||Time after leaving a malarial endemic area|
|Chloroquine||Yes||300mg||weekly||Yes||Yes||1 week||4 weeks|
|Doxycycline||No||100mg||daily||No||8 years or older||2 days||4 weeks|
|Mefloquine||Yes†||250mg||weekly||No‡||> 5kg||2 weeks||4 weeks|
|Proguanil||Yes||200mg||daily||Yes||Yes||1 day||4 weeks|
|Atovaquone / proguanil||No||250mg / 100mg||daily||No||> 11 kg||1 day||1 week|
* for falciparum malaria
† resistance reported in Northern Thailand, Cambodia and Myanmar
‡ may be used in 2nd and 3rd trimesters
Doxycycline is very effective prophylaxis for chloroquine-resistant P. falciparum. There are no known serious adverse events from its long-term use, however daily dosing is a disadvantage and may lead to poor compliance. Vaginal thrush and photosensitivity may be troublesome adverse effects. It should be swallowed with food or an adequate quantity of water to avoid oesophagitis. An advantage of doxycycline is that it may provide some protection against infectious diarrhoea, tick-borne infections, scrub typhus, leptospirosis and some sexually transmitted diseases such as chlamydia. It is contraindicated in pregnant or breastfeeding women and children under eight years of age.
Mefloquine has been extensively used and is very effective prophylaxis for people living in areas where chloroquine-resistant P. falciparum is endemic. Weekly administration helps compliance, and there has been no increase in adverse events with long-term use.2 In prophylactic doses it is generally well tolerated with studies showing no significant differences in adverse events compared to other antimalarial regimens apart from atovaquone/proguanil.2 Although severe neuropsychiatric adverse events are rare (estimated 1:10 000 users), it is not recommended for those who have underlying neuropsychological problems (e.g. epilepsy, depression). Some people experience mild neuropsychological effects such as headache, dizziness, mood changes, insomnia and vivid nightmares. As most adverse effects will occur within the first month of use, a trial of mefloquine for 3-4 weeks before departure to test its tolerability in long-term travellers is often worthwhile. We do not recommend mefloquine in the first trimester of pregnancy unless there is a significant risk of chloroquine-resistant P. falciparum malaria, although there is mounting evidence to support its safety. It is also not recommended for children less than 5 kg in weight.
This combination is highly effective prophylaxis for chloroquine-resistant falciparum malaria. Although gastrointestinal symptoms can occur it is well tolerated, and comparative studies show it to be better tolerated than mefloquine, doxycycline and chloroquine/proguanil for prophylaxis.1 The use of the combination by long-term travellers is limited by its expense, a lack of long-term safety data and concerns about the development of resistance. We therefore currently do not routinely recommend its use for prophylaxis.
Chloroquine has the advantage of improved compliance because it is taken weekly. It can be used by pregnant women and young children and is generally well tolerated. The main adverse effects are gastrointestinal upsets and a bitter taste. Long-term use is safe, however regular retinal screening is recommended after five years of continuous use as there is a potential risk of cumulative retinal toxicity. Chloroquine reduces the effectiveness of intradermal rabies vaccine necessitating vaccination by the intramuscular route.
The use of chloroquine is limited by the resistance of P. falciparum parasites. It may still have a role, taken alone or combined with proguanil, in areas with low resistance rates or low transmission risk (e.g. India) or where medical care is readily accessible. Chloroquine may also be used if the patient is intolerant of or reluctant to take other regimens or will have problems with compliance.
The use of proguanil is limited by the widespread resistance of P. falciparum parasites, and lack of compliance with its daily dosing. It is mainly used in combination with chloroquine. Long-term use is safe, but there is a low incidence of adverse effects (mouth ulcers). It can be used in pregnancy and childhood.
Long-term travellers may choose not to take chemoprophylaxis, but instead rely on mosquito avoidance measures and the use of a reliable treatment if they become infected. If symptoms suggestive of malaria develop, they either seek urgent medical attention, if available within 24 hours, or take an emergency self-treatment course effective for the local malarial resistance patterns, preferably after using a self-diagnosis malarial kit. For standby treatment to be an option, the traveller needs to be well educated about the various symptoms that suggest malarial infection, and be precisely instructed on how to take the treatment. Self-treatment should always be followed by a medical consultation as soon as possible.
|Medication||Resistance||Adult dose||Reduce dose for children|
|Atovaquone / proguanil||No||four tablets (250 mg/100 mg) daily for three days||< 40 kg|
|Mefloquine||Yes*||500 mg immediately, repeated eight hours later†||< 50 kg|
|Sulphadoxine-pyrimethamine||Yes||three tablets (500 mg/25 mg)||< 13 years|
|Quinine||No||600 mg three times daily for seven days‡||< 50 kg|
* Resistance has been reported in Thailand, Cambodia and Myanmar
† If < 60 kg use 250 mg for second dose
‡ Combined with sulphadoxine-pyrimethamine (in sensitive areas, three tablets) or doxycycline (100 mg twice daily for seven days)
This regimen is highly effective for all forms of malaria, there is no reported resistance and adverse effects are minimal. The combination can be used after any of the chemoprophylactic drugs. Its major disadvantage is that it is significantly more expensive than other regimens.
This is an effective treatment in areas without reported resistance. A disadvantage is the high risk of adverse reactions (28-59%) associated with a treatment course.3 There are rare reports of severe neurological disturbances such as depression, psychosis and seizures.4 Emergency treatment with mefloquine is not recommended for people taking mefloquine for prophylaxis as there is an increased risk of adverse events.
This offers a simple, inexpensive and well-tolerated
regimen. However, it is no longer recommended in Africa, South America and South-East Asia because of increasing resistance. Uncommon, but serious, complications such as Stevens-Johnson syndrome and agranulocytosis, further limit its use.
This is highly effective against chloroquine-resistant malaria. However, its use is limited by a high incidence of adverse effects, and a complex, prolonged regimen requiring combination with another drug.
This is an effective treatment which is active against chloroquine-resistant P. falciparum. It is available via the Special Access Scheme, however, we do not recommend it because of its potential for fatal cardiac arryhthmias (especially in those on mefloquine chemoprophylaxis) and the availability of safer, effective alternative drugs.
Relatively inexpensive kits (e.g. ICT, Parasight F, RAPIMAL) have been developed which allow the rapid self-diagnosis of malaria. They are immunochromatographic card tests that use a drop of blood to detect malarial antigens. These tests have been shown in numerous laboratory studies to be very sensitive and specific for falciparum malaria. As such they are well suited to long-term travellers who may not be taking prophylaxis, or who are taking a less effective prophylactic regimen, especially in those who are living without close access to medical care. They are easy to carry, simple to use, and give a quick result. However, studies have shown that many travellers have difficulty using them accurately in the field. These kits should therefore only be prescribed after appropriate instruction and training in their use.5
There is no ready solution to antimalarial prophylaxis for the long-term traveller or expatriate. Their doctor needs to be familiar with malarial epidemiology and drug resistance patterns in the area to be visited, the pros and cons of the various prophylaxis and treatment options, and the medical history and personality of the traveller involved. With this in mind, and with the provision of sufficient time for discussion with, and education of, the traveller, a suitable and safe regimen can usually be devised.
E-mail: [email protected]
See resources on the following web sites:
US Centers for Disease Control and Prevention www.cdc.gov/travel
World Health Organization www.who.int/ith/
Health Canada www.travelhealth.gc.ca
Department of Public Health and Travel Medicine, James Cook Universitywww.jcu.edu.au/school/phtm/PHTM/putravel.htm
Conflict of interest: none declared
The following statements are either true or false.
1. Doxycycline is unsuitable for malaria chemoprophylaxis in pregnant women.
2. Mefloquine should not be used for self-treatment by someone who has been taking it for malaria chemoprophylaxis.
Answers to self-test questions
Department of Medicine and Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne